Cognition Therapeutics, Inc.
CGTX
$1.20
$0.021.70%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -1.75% | -15.27% | -19.48% | -15.78% | -28.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.49% | -55.92% | -4.77% | -2.32% | -29.40% |
| Operating Income | -27.49% | 55.92% | 4.77% | 2.32% | 29.40% |
| Income Before Tax | 57.37% | 50.39% | 4.36% | 7.33% | 3.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 57.37% | 50.39% | 4.36% | 7.33% | 3.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 57.37% | 50.39% | 4.36% | 7.33% | 3.67% |
| EBIT | -27.49% | 55.92% | 4.77% | 2.32% | 29.40% |
| EBITDA | -27.68% | 55.94% | 4.71% | 2.32% | 29.46% |
| EPS Basic | 78.52% | 74.30% | 39.84% | 49.43% | 33.12% |
| Normalized Basic EPS | 79.00% | 74.30% | 39.80% | 49.44% | 31.46% |
| EPS Diluted | 78.65% | 74.72% | 38.89% | 48.40% | 34.01% |
| Normalized Diluted EPS | 79.00% | 74.30% | 39.80% | 49.44% | 31.46% |
| Average Basic Shares Outstanding | 98.31% | 92.86% | 58.98% | 83.27% | 44.00% |
| Average Diluted Shares Outstanding | 98.31% | 92.86% | 58.98% | 83.27% | 44.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |